Regeneron Pharmaceuticals, Inc. REGN
Set alert
At close · Oct 30
After hours · Oct 30, 4:44 PM ET
- YTD
- +20.21%
- 1 year
- +41.87%
- Open
- 869.43
- Prev close
- 818.77
- Mkt cap
- 95.53B
- Vol
- 2.85M
- Avg vol
- 707.20K
- EPS
- 40.44
- P/E
- 22.94
- Div yield
- 0.46%
More statistics
- Low
- 839.08
- High
- 935.34
- Forward P/E
- 14.74
- Beta
- 0.15
- Short ratio
- 2.78
- Inst. own
- 93.18%
- Dividend
- 3.76
- Ex-div date
- Aug 17, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 791.28
- 200-d avg
- 736.67
- 1y target
- 869.07
5Y chart
Events in this range
- Feb 20, 2025Dividend: 0.88
- May 20, 2025Dividend: 0.88
- Aug 18, 2025Dividend: 0.88
- Oct 28, 2025Earnings: 11.83; estimate 9.65; surprise 22.59%
- Nov 20, 2025Dividend: 0.88
- Jan 30, 2026Earnings: 11.44; estimate 10.74; surprise 6.52%
- Feb 20, 2026Dividend: 0.94
- Apr 29, 2026Earnings: 9.47; estimate 8.91; surprise 6.29%
- May 20, 2026Dividend: 0.94
- Jul 30, 2026Earnings: 14.29; estimate 10.16; surprise 40.65%
- Aug 18, 2026Dividend: 0.94
- Oct 7, 2026Rating: Truist Securities · Buy → Buy
- Oct 8, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 15, 2026Rating: UBS · Neutral → Buy
- Oct 19, 2026Rating: Piper Sandler · Overweight → Overweight
- Oct 21, 2026Rating: TD Cowen · Buy → Buy
- Oct 28, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 30, 2026Earnings: 20.07; estimate 16.51; surprise 21.56%
Signals (91)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 2, 2025 | 1 year ago |
| RSI: Oversold | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | May 5, 2025 | 1 year ago |
| RSI: Oversold | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| RSI: Oversold | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 17, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Feb 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Feb 3, 2025 | 1 year ago |
| RSI: Oversold | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 23, 2024 | 2 years ago |
| RSI: Overbought | Aug 5, 2024 | 2 years ago |
| RSI: Overbought | Jul 8, 2024 | 2 years ago |
| RSI: Overbought | Jun 10, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 3, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 1, 2024 | 2 years ago |
| RSI: Overbought | Mar 18, 2024 | 2 years ago |
| RSI: Overbought | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| MACD: Sell Signal | May 1, 2023 | 3 years ago |
| SMA: Bullish | Mar 20, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 27, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 26, 2022 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | May 30, 2022 | 4 years ago |
| SMA: Bearish | May 30, 2022 | 4 years ago |
| SMA: Bullish | May 23, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| RSI: Overbought | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 7, 2022 | 4 years ago |
| SMA: Bearish | Feb 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 95.31B
- Enterprise value
- 76.47B
- Trailing P/E
- 22.89
- Forward P/E
- 14.74
- PEG ratio
- 1.40
- Price / sales
- 6.14
- Price / book
- 2.93
- EPS (TTM)
- 40.44
- Beta
- 0.15
- Dividend yield
- 0.46%
- Payout ratio
- 9.00%
- Profit margin
- 27.87%
- Revenue (TTM)
- 15.53B
- Revenue growth
- 16.70%
- Free cash flow
- 3.07B
- Total cash
- 7.99B
- Total debt
- 2.71B
- Return on equity
- 14.04%
- Shares outstanding
- 101.14M
- Short % of float
- 2.19%
- 50-day average
- 791.28
- 200-day average
- 736.67
Analyst view
Consensus: buy
- Target (low)
- 730.00
- Target (mean)
- 869.07
- Target (high)
- 1,030.00
- Strong buy4
- Buy15
- Hold8
- Sell0
- Strong sell1
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 20.50.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 24.25 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 16.51 | 20.07 | +3.56 | +21.56% |
| Jul 30, 2026 | Jun 30, 2026 | 10.16 | 14.29 | +4.13 | +40.65% |
| Apr 29, 2026 | Mar 31, 2026 | 8.91 | 9.47 | +0.56 | +6.29% |
| Jan 30, 2026 | Dec 31, 2025 | 10.74 | 11.44 | +0.70 | +6.52% |
| Oct 28, 2025 | Sep 30, 2025 | 9.65 | 11.83 | +2.18 | +22.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Oct 19, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 15, 2026 | UBS | up | Neutral | Buy |
| Oct 8, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regeneron.com
News
- Regeneron: 3 Key Takeaways for Long-Term Investors
- Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street
- REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
- Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Nasdaq Tumbles Over 3%, Chip Stocks Sink: Stock Market Today
- Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
- Regeneron Is Just Getting Started
- What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
- Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Your note
Sign in to keep a note on REGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN MICHAEL S | Director | Stock Award(Grant) | Jan 1, 2026 | 12,865 |
| FENIMORE CHRISTOPHER R | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 17, 2026 | 23,505 |
| LAROSA JOSEPH J | General Counsel | Conversion of Exercise of derivative security | Aug 18, 2026 | 45,595 |
| MCCOURT MARION E | Officer | Stock Award(Grant) | Dec 4, 2025 | 15,567 |
| MURPHY ANDREW J | Officer | Stock Award(Grant) | Dec 4, 2025 | 56,437 |
| RYAN ARTHUR F. | Director | Sale | Jul 1, 2026 | 17,303 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.01% | 9,113,506 | 8.44B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.56% | 6,629,759 | 6.14B | Jun 29, 2026 |
| Dodge & Cox Inc. | 4.82% | 4,871,137 | 4.51B | Jun 29, 2026 |
| State Street Corporation | 4.78% | 4,834,688 | 4.48B | Jun 29, 2026 |
| Invesco Ltd. | 3.90% | 3,940,665 | 3.65B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.73% | 3,774,199 | 3.49B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.23% | 3,270,896 | 3.03B | Jun 29, 2026 |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.09% | 3,121,304 | 2.89B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.56% | 2,588,231 | 2.40B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 2,112,569 | 1.96B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.29% | 1,306,480 | 1.21B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.28% | 1,297,077 | 1.20B | Aug 30, 2026 |